MX2013009380A - Metodo para diagnosticar cancer y kit de diagnostico usando medicion de actividad de celulas nk. - Google Patents

Metodo para diagnosticar cancer y kit de diagnostico usando medicion de actividad de celulas nk.

Info

Publication number
MX2013009380A
MX2013009380A MX2013009380A MX2013009380A MX2013009380A MX 2013009380 A MX2013009380 A MX 2013009380A MX 2013009380 A MX2013009380 A MX 2013009380A MX 2013009380 A MX2013009380 A MX 2013009380A MX 2013009380 A MX2013009380 A MX 2013009380A
Authority
MX
Mexico
Prior art keywords
measurement
cell activity
diagnosis kit
diagnosing cancer
cancer
Prior art date
Application number
MX2013009380A
Other languages
English (en)
Other versions
MX361731B (es
Inventor
Myun Lee Jae
Joo Chun Yoon
Sang Woo Park
Jong Sun Kim
Original Assignee
Atgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atgen Co Ltd filed Critical Atgen Co Ltd
Publication of MX2013009380A publication Critical patent/MX2013009380A/es
Publication of MX361731B publication Critical patent/MX361731B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan un método para diagnosticar cáncer, un kit de diagnóstico y las composiciones útiles para medición de la actividad de células NK. La incidencia del cáncer puede diagnosticarse al vigilar cambios en el sistema inmunitario in vivo a través de la medición de la actividad de células NK en la sangre. De esta manera, la incidencia del cáncer puede predecirse fácilmente como se describe en la presente usando una muestra de sangre de un sujeto.
MX2013009380A 2011-02-14 2012-02-10 Método para diagnosticar cáncer y kit de diagnóstico usando medición de actividad de células nk. MX361731B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110012983A KR20120093002A (ko) 2011-02-14 2011-02-14 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
PCT/IB2012/000259 WO2012110878A2 (en) 2011-02-14 2012-02-10 Method of diagnosing cancer and diagnosis kit using measurement of nk cell activity

Publications (2)

Publication Number Publication Date
MX2013009380A true MX2013009380A (es) 2013-12-16
MX361731B MX361731B (es) 2018-12-14

Family

ID=46672988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009380A MX361731B (es) 2011-02-14 2012-02-10 Método para diagnosticar cáncer y kit de diagnóstico usando medición de actividad de células nk.

Country Status (20)

Country Link
US (2) US11442069B2 (es)
EP (1) EP2676139B1 (es)
JP (5) JP6629497B2 (es)
KR (3) KR20120093002A (es)
CN (1) CN103370622B (es)
AU (2) AU2012219184A1 (es)
BR (1) BR112013020454B1 (es)
CA (1) CA2826053C (es)
CL (1) CL2013002361A1 (es)
DK (1) DK2676139T3 (es)
EA (1) EA038959B1 (es)
ES (1) ES2797549T3 (es)
IL (1) IL227952B (es)
MX (1) MX361731B (es)
MY (1) MY175351A (es)
RU (1) RU2635194C2 (es)
SG (1) SG192247A1 (es)
TW (2) TWI668445B (es)
UA (1) UA120697C2 (es)
WO (1) WO2012110878A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120093002A (ko) * 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
WO2015069187A1 (en) * 2013-11-05 2015-05-14 Agency For Science, Technology And Research Bladder Carcinoma Biomarkers
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
WO2017204446A2 (ko) * 2016-05-24 2017-11-30 울산대학교 산학협력단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
CN106085958A (zh) * 2016-08-04 2016-11-09 英普乐孚生物技术(上海)有限公司 一种nk细胞的制备方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106222140A (zh) * 2016-08-04 2016-12-14 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基及其配制方法
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
KR102090698B1 (ko) * 2017-08-24 2020-04-23 연세대학교 산학협력단 암의 진단, 모니터링, 또는 예후 예측을 위해 생체 외 인터페론-감마의 양을 측정하는 방법
JP2022546486A (ja) * 2019-08-29 2022-11-04 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 細胞凍結保存培地
EP4015526A4 (en) * 2019-09-25 2023-01-04 Leto Laboratories Co., Ltd RECOMBINED INTERLEUKIN-15 ANALOG
WO2021108389A1 (en) * 2019-11-29 2021-06-03 Nkmax Co., Ltd. Method of producing natural killer cells and compositions thereof
CN113533729A (zh) * 2021-06-15 2021-10-22 北京大学人民医院 一种鉴定aml患者骨髓中nk细胞耗竭的研究方法及其应用
AU2022413768A1 (en) * 2021-12-17 2024-06-13 Fujifilm Diosynth Biotechnologies Uk Limited Sequences and methods for production of recombinant biological molecules in vesicles
KR20230156518A (ko) 2022-05-06 2023-11-14 (주)다이오진 엑소좀 내의 인터페론 감마 유전자 측정을 이용한 암 조기 진단 방법 및 진단 키트
CN115247149B (zh) * 2022-08-22 2023-06-16 华域生物科技(天津)有限公司 适用于nk细胞的培养基组合物及培养方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA888978B (en) * 1987-12-04 1990-07-25 Du Pont Immobilized interleukin 2 and interleukin 2 containing a carboxylterminal extension
KR100340091B1 (ko) * 1993-08-09 2002-09-27 베르찌 이스트반 킬러세포개재세포용해를위한암세포감작용약학적제제
EP0820299B1 (en) * 1995-02-06 2002-04-24 Genetics Institute, Inc. Formulations for il-12
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2003016513A1 (en) 2001-08-13 2003-02-27 Junjiro Tsuchiyama Epstein-barr virus-negative nk cell line
JP2005517389A (ja) * 2001-11-20 2005-06-16 アトゲン カンパニー リミティッド 環境ストレス耐性を有する新規のペプチド及びこれを含む融合蛋白質
WO2003082206A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
JP2004305095A (ja) 2003-04-07 2004-11-04 Limuloid Science Kk 細胞活性化検出方法
CN1297567C (zh) * 2003-06-13 2007-01-31 马菁 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
WO2005014642A2 (en) * 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
WO2005013950A2 (en) 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
US20050112130A1 (en) 2003-11-05 2005-05-26 Bhat Neelima M. Enhanced B cell cytotoxicity of CDIM binding antibody
US20050203010A1 (en) * 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
KR100565764B1 (ko) * 2005-05-02 2006-03-28 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및 이를포함하는 융합 단백질
JP4653465B2 (ja) 2004-10-25 2011-03-16 泰信 小林 ナチュラルキラー細胞の増殖促進方法およびそれに用いる培養組成物
WO2006110577A2 (en) * 2005-04-08 2006-10-19 Morningside Venture Investments Limited Use of fril proteins for reducing the production of pro-inflammatory cytokines
WO2008013975A2 (en) * 2006-07-28 2008-01-31 The Research Foundation Of State University Of New York Methods and kits for measurement of lymphocyte function
US20080138833A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
CA2675291C (en) 2007-01-11 2017-05-23 Novo Nordisk A/S Killer ig-like receptor (kir) antibodies, formulations, and uses thereof
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트

Also Published As

Publication number Publication date
KR101438573B1 (ko) 2014-09-12
CA2826053C (en) 2021-05-25
AU2017202628B2 (en) 2019-08-22
CN103370622A (zh) 2013-10-23
RU2635194C2 (ru) 2017-11-09
KR20120093002A (ko) 2012-08-22
KR20130136012A (ko) 2013-12-11
RU2013141487A (ru) 2015-03-27
WO2012110878A3 (en) 2013-01-31
US20220229070A1 (en) 2022-07-21
JP2017129597A (ja) 2017-07-27
ES2797549T3 (es) 2020-12-02
MX361731B (es) 2018-12-14
WO2012110878A2 (en) 2012-08-23
EP2676139B1 (en) 2020-05-06
JP2022043119A (ja) 2022-03-15
IL227952A0 (en) 2013-09-30
US11442069B2 (en) 2022-09-13
NZ614345A (en) 2015-09-25
DK2676139T3 (da) 2020-06-15
JP6798922B2 (ja) 2020-12-09
NZ710432A (en) 2017-04-28
AU2012219184A1 (en) 2013-09-05
IL227952B (en) 2019-01-31
JP2023115006A (ja) 2023-08-18
TWI681191B (zh) 2020-01-01
JP6629497B2 (ja) 2020-01-15
TWI668445B (zh) 2019-08-11
TW201245718A (en) 2012-11-16
CN103370622B (zh) 2018-02-13
BR112013020454A8 (pt) 2022-11-29
KR101341538B1 (ko) 2013-12-18
CL2013002361A1 (es) 2014-06-27
EP2676139A2 (en) 2013-12-25
TW201741670A (zh) 2017-12-01
KR20130032410A (ko) 2013-04-01
EP2676139A4 (en) 2014-12-03
JP2014510517A (ja) 2014-05-01
BR112013020454A2 (pt) 2016-10-18
MY175351A (en) 2020-06-22
UA120697C2 (uk) 2020-01-27
US20140017713A1 (en) 2014-01-16
EA038959B1 (ru) 2021-11-15
CA2826053A1 (en) 2012-08-23
BR112013020454B1 (pt) 2023-03-21
AU2017202628A1 (en) 2017-05-11
EA201391187A1 (ru) 2013-12-30
JP2019207242A (ja) 2019-12-05
SG192247A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
MY175351A (en) Method and kit for measurement of nk cell activity
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
EP4339613A3 (en) Body fluid sampling arrangement
MX2013000916A (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
WO2012173976A3 (en) Methods and apparatus for assessing activity of an organ and uses thereof
EP2535005A4 (en) ULTRASONIC DIAGNOSTIC DEVICE AND METHOD FOR MEASURING THE THICKNESS OF THE INTIMA MEDIA COMPLEX
EP2781918A4 (en) MEANS FOR THE FAST DETECTION OF ADIPSIN FOR THE DIAGNOSIS OF PREECLAMPSIA, TESTS AND PRODUCTION METHOD THEREFOR
WO2012054783A3 (en) Internal focus reference beads for imaging cytometry
MX359328B (es) Metodo para el diagnostico de enfermedad de niemann-pick.
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2014053996A3 (en) Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs
WO2014087255A3 (en) Systems and methods for monitoring biological fluids
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
EP2799546A4 (en) RADIUS EXPOSURE DIAGNOSIS MARKER IGFBP-5, COMPOSITION FOR RADIOGRAPHIC EXPOSURE DIAGNOSIS BY MEASUREMENT OF EXPRESSIVE LEVEL OF MARKER, RADIOGRAPHIC EXPOSURE DIAGNOSIS KIT WITH COMPOSITION AND METHOD FOR DIAGNOSIS OF RADIATION EXPOSURE USING MARKER
WO2012008747A3 (ko) 피부 진단 방법 및 키트
GB201107557D0 (en) Method
WO2013050950A3 (en) Method for monitoring, diagnosis and/or prognosis of hypoxia related disorders using nfat5
WO2012024302A3 (en) Biomarkers of cancer
MX348303B (es) Métodos y composiciones para la evaluación de lesión renal utilizando ácido hialurónico.
WO2011153590A8 (en) Use of interferon epsilon in methods of diagnosis and treatment
MX337369B (es) Biomarcador para el diagnostico de cancer de mama.
UA42838U (ru) Способ диагностики остеопенического синдрома у женщин в менопаузе с заболеваниями сердечно-сосудистой системы
NZ625725A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
FG Grant or registration